Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti, S., Hurt, C. B., Stephenson, K. E., Huang, Y., Paez, C. A., Yu, C., Yen, C., Hanscom, B., He, Z., Miner, M. D., Gamble, T., Heptinstall, J., Seaton, K. E., Domin, E., Lin, B. C., McKee, K., Doria-Rose, N., Regenold, S., Spiegel, H., … Afemata, S. (2024). Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(24)00247-9
Authors:
Srilatha Edupuganti
Christopher B Hurt
Kathryn E Stephenson
Yunda Huang
Carmen A Paez
Chenchen Yu
Catherine Yen
Brett Hanscom
Zonglin He
Maurine D Miner
Theresa Gamble
Jack Heptinstall
Kelly E Seaton
Elizabeth Domin
Bob C Lin
Krisha McKee
Nicole Doria-Rose
Stephanie Regenold
Hans Spiegel
Maija Anderson
Nadia McClosky
Lily Zhang
Estelle Piwowar-Manning
Margaret E Ackerman
Michael Pensiero
Bonnie J Dye
Raphael J Landovitz
Kenneth Mayer
Marc Siegel
Magdalena Sobieszczyk
Stephen R Walsh
Lucio Gama
Dan H Barouch
David C Montefiori
Georgia D Tomaras
Affiliated Authors:
Magdalena Sobieszczyk
Columbia Affiliation:
elink
Publication Type:
Article
Unique ID:
10.1016/s2352-3018(24)00247-9
PMID:
39667379
DOI:
10.1016/s2352-3018(24)00247-9
Journal:
Lancet HIV
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: